Pre-analytical, analytical and post-analyticalconsiderations in glucose point-of-care testing by Jacobsz, Madelene & Dednam, Marita
BRIEWE
805
September 2007, Vol. 97, No. 9  SAMJ
tent at the race finish, while the other was certified dead later 
in a local private hospital.
Previous medico-legal autopsy diagnoses after sport-
related deaths in our personal experience in Durban included 
cardiomyopathy, coronary artery disease, Marfan’s syndrome 
and ruptured cerebral berry aneurysms.  It is regrettable that 
autopsies were not performed in the above cases.  Whether 
they should have been considered natural or unnatural may 
be debatable, but postmortem examinations could have 
served to establish the cause/s and mechanism/s of death 
without need for speculation, and before considerations on 
their preventability.  Routine autopsy examinations in such 
instances would enlighten issues of familial/genetic study and 
counselling, scientific research into this area, and for ‘selective 
pre-competition screening’ in sport.
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Pre-analytical, analytical and post- 
analytical considerations in glucose 
point-of-care testing
To the Editor: Point-of-care (POC) blood glucose monitoring 
has become an accepted method to evaluate patients in the 
hospital setting. In most situations, the method is accurate with 
a short turnaround time, which expedites treatment decisions. 
The important issue to keep in mind is that any point of care 
test is subject to pre-analytical, analytical and post-analytical 
variability. 
A case in point: a neonate who presented with prolonged 
jaundice, liver dysfunction (elevated transaminase, 
coagulopathy), and renal tubular dysfunction (normal anion 
gap metabolic acidosis and glucosuria), was treated with 
insulin after POC glucose values were reported to be above 15 
mmol/l. When the patient’s condition deteriorated, the POC 
glucose results were correlated with the laboratory plasma 
glucose concentrations done on the Beckman LX, using a 
glucose oxidase ion selective electrode method. The laboratory 
values were consistently low (discrepant to POC values). The 
urine showed 4+ galactose and the red cells showed reduced 
galactose-1-phosphate uridyl transferase (GALT) activity. The 
patient was diagnosed with galactosaemia. 
POC blood glucose meters have evolved rapidly and 
new-generation meters can exclude many of the previously 
encountered pre-analytical problems including inadequate 
sample volume, improper application and timing, removal of 
excess blood and lockout function if controls are out of range. 
Variables that may influence the analytical process include 
the haematocrit, environmental temperature or humidity, 
hypoxia, high triglyceride concentrations, and inaccuracy 
at very high and very low concentrations.1 Method-specific 
interferences are also encountered, e.g. the POC device in this 
case (Roche Accu-Check Active) is a glucose dehydrogenase 
pyrroloquinolinequinone (GDH-PQQ)-based glucose 
measuring system. This system is not specific for glucose 
and may give false elevated glucose values in the presence 
of maltose, xylose or galactose (Accu-Check Active test strips 
package insert).  Post-analytical factors that influence the 
interpretation of the result are whether a plasma or serum 
value is reported and the unit in which the result is reported. 
Recently, an International Federation of Clinical Chemistry 
(IFCC) working group recommended that all meters must 
be harmonised to the concentration of glucose in plasma, 
irrespective of the type of sample used.1,2
When a POC device is used, the clinician should always 
familiarise himself with the test method and the influence 
of possible interferences on the method. Methods using 
glucose dehydrogenase with NAD as co-factor (GDH-NAD), 
hexokinase or glucose oxidase are specific for glucose and do 
not exhibit interference as a result of interfering sugars.3
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Hypertension: Holding on to your ACEs 
may be a good bet
To the Editor: The recently published South African 
Hypertension Guideline1 provides a comprehensive review 
of the causes and risks of abnormal blood pressure and 
of its treatment, but falls short of offering a cost-effective 
approach to managing the burden. Understanding the causes 
of hypertension, the morbidity associated with it, and the 
effective treatments are necessary, but not sufficient, conditions 
for a cost-effective programme.2,3 Also, adding to the debate, 
one has to look at this from another perspective.
In clinical practice, it is often assumed that angiotensin 
receptor blockers (ARBs) and angiotensin-converting enzyme 
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